Epiminder Limited (ASX:EPI) has disclosed that Chief Financial Officer and Company Secretary Mark McLellan has tendered his resignation to pursue an opportunity outside the company, with his departure scheduled for 26 February 2027 to allow for an orderly handover.

Key Points

  • Mark McLellan has resigned as Chief Financial Officer and Company Secretary of Epiminder Limited.
  • McLellan will remain in his role until 26 February 2027 to facilitate an orderly handover.
  • The company will commence a process to identify a suitable replacement.
  • The board thanked McLellan for his contribution to the company.

Resignation of Mark McLellan as CFO and Company Secretary

Epiminder Limited disclosed on 4 November 2026 that Mark McLellan has tendered his resignation from his dual roles of Chief Financial Officer and Company Secretary. According to the filing, McLellan's decision to resign is to pursue an opportunity outside the company. The filing states that McLellan will remain in his current roles until 26 February 2027, with the extended notice period intended to ensure an orderly handover of his responsibilities. The filing was approved by the Chair of the company prior to release.

Replacement Search Process to Commence

Epiminder said it will commence a process to identify a suitable replacement for the CFO and Company Secretary roles vacated by McLellan. The company stated it will keep the market informed in due course regarding the outcome of that process. No further details regarding the search timeline, criteria, or any interim arrangements for the CFO and Company Secretary functions were disclosed in the filing. The board extended its thanks to McLellan for his contribution during his tenure at the company.

About Epiminder and the Minder Device

Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. The company's Minder® device is a minimally invasive implantable continuous EEG monitoring system that records bilateral subscalp EEG and transmits data via an external wearable and smartphone application to a secure cloud platform. According to the filing, the Minder® System was authorised by the US Food and Drug Administration via the de novo pathway. Epiminder is headquartered in Melbourne, Australia, and has offices in the United States.